2-D08 as a SUMOylation inhibitor induced ROS accumulation mediates apoptosis of acute myeloid leukemia cells possibly through the deSUMOylation of NOX2.
Sign Up to like & getrecommendations! Published in 2019 at "Biochemical and biophysical research communications"
DOI: 10.1016/j.bbrc.2019.04.079
Abstract: Acute myeloid leukemia (AML) is a heterogeneous clonal hematopoietic malignancy with poor survival and frequent relapse. Recently, a posttranslational modification of proteins with small ubiquitin-like modifiers (SUMO) has been notably implicated in a wide spectrum… read more here.
Keywords: sumoylation; accumulation; myeloid leukemia; ros accumulation ... See more keywords
A small-molecule SUMOylation inhibitor activates antitumor immune responses and potentiates immune therapies in preclinical models
Sign Up to like & getrecommendations! Published in 2021 at "Science Translational Medicine"
DOI: 10.1126/scitranslmed.aba7791
Abstract: Description TAK-981, a first-in-class small-molecule SUMOylation inhibitor, activates type I interferon signaling to promote antitumor immune responses in mice. Stopping SUMOylation to improve immune responses SUMOylation, a reversible posttranslational modification, can suppress type I interferon… read more here.
Keywords: sumoylation; tak 981; small molecule; immune responses ... See more keywords
SUMOylation inhibitor subasumstat potentiates rituximab activity by IFN1-dependent macrophage and NK cell stimulation.
Sign Up to like & getrecommendations! Published in 2022 at "Blood"
DOI: 10.1182/blood.2021014267
Abstract: SUMOylation is a reversible post-translational modification that has been implicated in the regulation of various cellular processes including inflammatory responses and expression of Type I interferons (IFN1). In this report, we have explored the activity… read more here.
Keywords: cell; tak 981; activity; sumoylation inhibitor ... See more keywords
TAK-981, a SUMOylation inhibitor, suppresses AML growth immune-independently.
Sign Up to like & getrecommendations! Published in 2023 at "Blood advances"
DOI: 10.1182/bloodadvances.2022007956
Abstract: Acute myeloid leukemia (AML) generally has an unsatisfactory prognosis despite recent introduction of new regimens including targeted agents and antibodies. To find a new druggable pathway, we performed integrated bioinformatic pathway screening on large OHSU… read more here.
Keywords: aml; sumoylation; tak 981; sumoylation inhibitor ... See more keywords